NCT00761228View on ClinicalTrials.gov

Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury

PHASE2SuspendedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Brain Injury
Interventions
DRUG

Apomorphine

Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.

DRUG

Placebo

Patients will receive a continues subcutaneous infusion of saline solution.

Trial Locations (1)

02114

Spaulding Rehabilitation Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

FDA Office of Orphan Products Development

FED

lead

NeuroHealing Pharmaceuticals Inc.

INDUSTRY

NCT00761228 - Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury | Biotech Hunter | Biotech Hunter